{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:56:46Z","timestamp":1792796206411,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-019-1066-z","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T14:44:43Z","timestamp":1549896283000},"page":"341-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":184,"title":["Sintilimab: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"issue":"26","key":"1066_CR1","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","volume":"1","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Armand P, Wright KT, et al. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643\u201354.","journal-title":"Blood Adv."},{"issue":"1","key":"1066_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.","journal-title":"J Hematol Oncol."},{"issue":"5","key":"1066_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704\u201315.","journal-title":"Am J Hematol"},{"key":"1066_CR4","unstructured":"Innovent Biologics. China\u2019s NMPA approves Innovent\u2019s anti-PD-1 antibody Tyvyt\u00ae (sintilimab injection) for Hodgkin\u2019s lymphoma [media release]. 26 Dec 2018. http:\/\/innoventbio.com\/en\/#\/news\/123 ."},{"key":"1066_CR5","volume-title":"Tyvyt\u00ae (sintilimab): Chinese prescribing information","author":"Innovent Biologics","year":"2019","unstructured":"Innovent Biologics. Tyvyt\u00ae (sintilimab): Chinese prescribing information. Suzhou: Innovent Biologics; 2019."},{"key":"1066_CR6","unstructured":"Innovent Biologics. Innovent receives an approval from the US FDA to initiate clinical trials for its anti-CD47 monoclonal antibody IBI-188 [media release]. 29 Sept 2018. http:\/\/innoventbio.com\/en\/#\/news\/111 ."},{"key":"1066_CR7","unstructured":"Eli Lilly and Company. Lilly and Innovent Biologics announce a strategic alliance to bring potential oncology therapies to patients in China and around the world [media release]. 20 Mar 2015. http:\/\/lilly.mediaroom.com\/ ."},{"key":"1066_CR8","unstructured":"Eli Lilly and Company. Lilly and Innovent Biologics expand their strategic alliance to include immuno-oncology bispecific antibodies in China and globally [media release]. 11 Oct 2015. http:\/\/lilly.mediaroom.com\/ ."},{"key":"1066_CR9","unstructured":"Innovent Biologics. Innovent announces global collaboration with Hutchison MediPharma to evaluate combination of sintilimab and fruquintinib in solid tumors [media release]. 29 Nov 2018. http:\/\/innoventbio.com\/en\/#\/news\/119 ."},{"issue":"2","key":"1066_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/abt\/tby005","volume":"1","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Wu W, et al. Preclinical characterization of sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antibody Ther. 2018;1(2):65\u201373.","journal-title":"Antibody Ther."},{"issue":"1","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12\u20139.","journal-title":"Lancet Haematol."},{"key":"1066_CR12","doi-asserted-by":"crossref","unstructured":"Xu JM, Jia R, Wang Y, et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors [abstract no. e15125]. J Clin Oncol. 2018;36(15 Suppl).","DOI":"10.1200\/JCO.2018.36.15_suppl.e15125"},{"key":"1066_CR13","unstructured":"Jia R, Li YL, Jin YS, et al. Efficacy and safety of anti-PD-1 antibody (IBI308) in treating advanced neuroendocrine neoplams [abstract no. 2143]. Neuroendocrinology. 2018;106(Suppl 1):230."},{"key":"1066_CR14","doi-asserted-by":"crossref","unstructured":"Ying K, Xu N, Jiang H, et al. Efficacy and safety of sintilimab combined with 1st line chemotherapy in advanced squamous cell non-small cell lung cancer [abstract no. OA08]. J Thorac Oncol. 2018;13 (12 Suppl):S1047.","DOI":"10.1016\/j.jtho.2018.10.018"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-1066-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-1066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-1066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T10:32:49Z","timestamp":1606473169000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-1066-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-1066-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"11 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}